stoxline Quote Chart Rank Option Currency Glossary
AcelRx Pharmaceuticals, Inc. (ACRX)
0.86  0.06 (7.5%)    01-09 16:00
Open: 0.7811
High: 0.875
Volume: 240,995
Pre. Close: 0.8
Low: 0.7784
Market Cap: 15(M)
Technical analysis
2024-03-22 4:46:09 PM
Short term     
Mid term     
Targets 6-month :  1.53 1-year :  1.88
Resists First :  1.31 Second :  1.61
Pivot price 1.29
Supports First :  0.83 Second :  0.69
MAs MA(5) :  1.21 MA(20) :  1.22
MA(100) :  0.83 MA(250) :  0.85
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  28.5 D(3) :  38
RSI RSI(14): 46.7
52-week High :  1.61 Low :  0.42
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ACRX ] has closed above bottom band by 4.4%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.18 - 1.18 1.18 - 1.19
Low: 1.06 - 1.07 1.07 - 1.08
Close: 1.11 - 1.12 1.12 - 1.14
Company Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Headline News

Fri, 24 May 2024
AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? - Yahoo Movies UK

Fri, 24 May 2024
Will AcelRx Pharmaceuticals (ACRX) Report Negative Q2 Earnings? What You Should Know - Yahoo Singapore News

Wed, 22 May 2024
When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Become Profitable? - Yahoo Lifestyle Australia

Wed, 15 May 2024
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Lifestyle UK

Tue, 09 Jan 2024
AcelRx Pharma (ACRX) to Rebrand as Talphera, Inc -

Tue, 09 Jan 2024
AcelRx Announces Rebranding With Name Change to Talphera, Inc. - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 0 (M)
Shares Float 17 (M)
Held by Insiders 1.203e+007 (%)
Held by Institutions 2.6 (%)
Shares Short 751 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.683e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 828.2 %
Return on Equity (ttm) -32.3 %
Qtrly Rev. Growth 370000 %
Gross Profit (p.s.) -147.89
Sales Per Share -98.31
EBITDA (p.s.) -6.42308e+006
Qtrly Earnings Growth -2.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -19 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.54
Stock Dividends
Dividend 0
Forward Dividend 508110
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android